MedStar Health continues to offer expert clinical care to and research treatment opportunities for patients with melanoma and other skin cancers within an interdisciplinary network based at both at MedStar Washington Hospital Center and MedStar Georgetown University Hospital. We are tightly linked to the Melanoma Research Program at the Georgetown Lombardi Comprehensive Cancer Center, which is our research engine (Georgetown Lombardi is one of 51 National Cancer Institute-Designated Comprehensive Cancer Centers in the US and the only such one in the District of Columbia). This partnership allows you access to cutting-edge clinical trials and the latest breakthroughs in cancer care. Our Melanoma/Skin Cancer team remains the most experienced and comprehensive group for the treatment of patients with all stages of skin cancers in the Greater Washington, D.C. area.
Georgetown Lombardi Comprehensive Cancer Center Offers Full Range of Latest Clinical and Research Approaches to Patient Care
The Georgetown Lombardi Comprehensive Cancer Center at MedStar Georgetown University Hospital is often curing patients with high-risk and distant metastatic melanoma with FDA-approved and research immunotherapy treatments. Now the standard of care and the backbone for new research studies, these immunotherapies work by restoring the function of tumor specific immune cells inside the tumor, enabling the immune system to fight the cancer on its own. These approaches are not chemotherapy and therefore do not have the side effects traditionally associated with chemotherapy. Instead, side effects are related to activation of the immune system and can be addressed without altering the effectiveness of the immunotherapy. Similar outcomes are now seen in a range of advanced skin cancers beyond melanoma.
The Georgetown Lombardi Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated comprehensive cancer center in the Washington, D.C. region.